MedTrace Logo

SAD and MAD Study of FTX-101 in Healthy Male Subjects

NCT06617546 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2025-06-18

No results posted yet for this study

Summary

This is a Phase 1, first-in-human (FIH), single-center, randomized, double-blind, placebo-controlled study in healthy male subjects. The study will include the following 2 parts:

* Part A: Single Ascending Dose (SAD) in healthy male subjects
* Part B: Multiple Ascending Dose (MAD) in healthy male subjects

Conditions

  • Healthy Volunteers

Interventions

DRUG

FTX-101

Lyophilized powder for subcutaneous injection

DRUG

Placebo

Lyophilized powder for subcutaneous injection

Sponsors & Collaborators

  • Find Therapeutics

    lead INDUSTRY

Principal Investigators

  • Martin K. Kankam, MD, PhD, MPH, FAPCR · Altasciences Clinical Kansas, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-14
Primary Completion
2025-04-17
Completion
2025-04-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06617546 on ClinicalTrials.gov